quinazolines has been researched along with Lymphoma, B-Cell in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH; Kim, WS; Park, C | 1 |
| Bouabdallah, K; Childs, BH; Demeter, J; Dimou, M; Dreyling, M; Follows, G; Garcia-Vargas, J; Hiemeyer, F; Kim, WS; Kosinova, M; Lenz, G; Leppä, S; Miriyala, A; Mollica, L; Morschhauser, F; Munoz, J; Nagler, A; Özcan, M; Rodrigues, L; Santoro, A; Stevens, DA; Trevarthen, D; Zinzani, PL | 1 |
| Arribas, AJ; Berthold, M; Bertoni, F; Cascione, L; Gaudio, E; Gritti, G; Jourdan, T; Kwee, I; Lange, M; Liu, N; Margheriti, F; Politz, O; Rinaldi, A; Rossi, D; Scalise, L; Sperl, C; Spriano, F; Stathis, A; Sturz, A; Tarantelli, C; Zucca, E | 1 |
| Buvaylo, V; Childs, BH; Dreyling, M; Fletcher, M; Leppä, S; Matasar, MJ; Pedersen, M; Santoro, A; Zinzani, PL | 1 |
| Bouabdallah, K; Childs, BH; Cupit, L; Demeter, J; Dreyling, M; Follows, GA; Garcia-Vargas, J; Giurescu, M; Hiemeyer, F; Kim, WS; Köchert, K; Kosinova, M; Lenz, G; Leppä, S; Liu, L; Mollica, L; Morschhauser, F; Nagler, A; Özcan, M; Panayiotidis, P; Peña, C; Santoro, A; Seidel, H; Stevens, DA; Trevarthen, D; Yin, S; Zinzani, PL | 1 |
| Burger, H; Cohen, RB; Eskens, FA; Hwang, J; Lewis, NL; Malik, S; Marshall, J; Ould-Kaci, M; Stopfer, P; Uttenreuther-Fischer, M | 1 |
| Goldman, B | 1 |
| Gray, ML; Khan, S; Zimmerman, R | 1 |
3 trial(s) available for quinazolines and Lymphoma, B-Cell
| Article | Year |
|---|---|
Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Feasibility Studies; Female; Humans; Immunotherapy; Lymphoma, B-Cell; Male; Middle Aged; Pyrimidines; Quinazolines; Rituximab | 2021 |
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Isoenzymes; Lymphoma, B-Cell; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Transcriptome | 2017 |
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
Topics: Afatinib; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Quinazolines; Tissue Distribution | 2013 |
5 other study(ies) available for quinazolines and Lymphoma, B-Cell
| Article | Year |
|---|---|
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Topics: Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Interleukin-6; Isoquinolines; Janus Kinase Inhibitors; Lymphoma, B-Cell; Lymphoma, T-Cell; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Purines; Pyrimidines; Quinazolines; STAT3 Transcription Factor; STAT5 Transcription Factor; Transfection; Tumor Suppressor Proteins | 2019 |
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diarrhea; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypertension; Lymphoma, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Pyrimidines; Quinazolines; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2020 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2020 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
Novel cancer therapies: targeting the molecules.
Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Gefitinib; Humans; Lymphoma, B-Cell; Medical Oncology; Neoplasms; Quinazolines; Rituximab | 2003 |